http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014184662-A3

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2fa48c7d0dcb506157bcc6583fc11884
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_09ad8b5b3bc0add056634855c0f0c720
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ac307b2e3be1b2014146c8d29cdf9690
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2846
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2013
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4178
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2846
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-286
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2013
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-209
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4178
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-52
filingDate 2014-03-14-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8387a692d42163f4bade0b2d6175c524
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cb03dc75e28905bbb0275ff6348a60b3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9469a3f0971c99c94813a91a292c052a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f6fc53095fbb267ba68aa3b52f3964f0
publicationDate 2015-04-02-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2014184662-A3
titleOfInvention Antiemetic extended release solid dosage forms
abstract A pharmaceutical formulation includes (1) a first dosage component comprising: a core comprising a non-ionic polymer matrix, a first amount of ondansetron or an equivalent amount of an ondansetron salt thereof dispersed within the matrix, and an electrolyte dispersed within the matrix; a first seal coat surrounding the core, the first seal coat comprising a non-ionic polymer matrix; and an immediate release drug layer surrounding the first seal coat, wherein the immediate release drug layer comprises a non-ionic polymer and a second amount of ondansetron or an equivalent amount of an ondansetron salt thereof dispersed therein; and (2) a second dosage component comprising: a core comprising a third amount of ondansetron or an equivalent amount of an ondansetron salt thereof, at least one filler, and a lubricant; and a coating surrounding the core, the coating comprising water and a mixture of methacrylic acid- alkyl acrylate copolymers with alkaline groups.
priorityDate 2013-03-14-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010196472-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008299197-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008200508-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005131045-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6090411-A
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4595
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396518
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID698135
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396519

Total number of triples: 39.